切换导航

EPZ004777

现货
Catalog No.
A4170
DOT1L抑制剂
组合的产品项目
规格价格库存 数量
10mM (in 1mL DMSO)
¥ 1,300.00
现货
5mg
¥ 1,100.00
现货
50mg
¥ 5,500.00
现货

电话: 021-55669583

邮箱: sales@apexbio.cn

全球经销商

Background

EPZ004777 is a specific small-molecule H3K79 methyltransferase DOT1L inhibitor that potently inhibits DOT1L in a radionuclide homogeneous assay with the half maximal inhibition concentration IC50 value of 400 pM and selectively kills a variety of MLL-rearranged leukemia cells, including an MLL-AF4 leukemia cell line MV4-11 and an MLL-AF9 leukemia cell line MOLM13 [1 & 2].

EPZ004777 has also been found to selectively inhibit the proliferation of MLL-AF10 and CALM-AF10 transformed cells in a dose dependent manner (IC50: 0.1 μM to 1 μM), in which the mRNA expression levels of two hallmark leukemogenic genes (Hoxa9 and Meis1) are suppressed by EPZ004777 in a concentration dependent manner [2].

Reference

References:
[1] Yu W, Chory EJ, Wernimont AK, Tempel W, Scopton A, Federation A, Marineau JJ, Qi J, Barsyte-Lovejoy D, Yi J, Marcellus R, Iacob RE, Engen JR, Griffin C, Aman A, Wienholds E, Li F, Pineda J, Estiu G, Shatseva T, Hajian T, Al-Awar R, Dick JE, Vedadi M, Brown PJ, Arrowsmith CH, Bradner JE, Schapira M. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun. 2012;3:1288. doi: 10.1038/ncomms2304.
[2] Chen L, Deshpande AJ, Banka D, Bernt KM, Dias S, Buske C, Olhava EJ, Daigle SR, Richon VM, Pollock RM, Armstrong SA. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia. 2013 Apr;27(4):813-22. doi: 10.1038/leu.2012.327. Epub 2012 Nov 9.

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt539.67
Cas No.1338466-77-5
FormulaC28H41N7O4
Solubility≥27 mg/mL in DMSO, ≥94.6 mg/mL in EtOH with ultrasonic, <2.45 mg/mL in H2O
Chemical Name1-[3-[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methyl-propan-2-ylamino]propyl]-3-(4-tert-butylphenyl)urea
SDF
Canonical SMILESCC(C)N(CCCNC(=O)NC1=CC=C(C=C1)C(C)(C)C)CC2C(C(C(O2)N3C=CC4=C3N=CN=C4N)O)O
运输条件试用装:蓝冰运输。 其他可选规格:常温运输或根据您的要求用蓝冰运输。
一般建议为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。

试验操作

细胞实验[1]:

细胞系

人类白血病细胞系MV4-11和Molm13细胞

溶解方法

在DMSO中的溶解度大于10 mM。为了获得更高的浓度,可以将离心管在37℃加热10分钟和/或在超声波浴中震荡一段时间。原液可以在-20℃以下储存几个月。

反应条件

96 h,10 μM

应用

EPZ004777是一个特异的DOT1L强效抑制剂,在放射性核素均相实验中的IC50为400 pM。它可以选择性的杀死含有和致癌MLL融合蛋白互作而定位异常的DOT1L的混合系白血病细胞。

动物实验[2]:

动物模型

8周龄的C57BL/6小鼠

剂量

向小鼠体内植入对照(15%乙醇,50% PEG300,35%水)或150 mg/ml EPZ004777的渗透泵,一周后更换渗透泵,继续给药一周。

应用

EPZ004777在小鼠中耐受性良好,没有明显的毒性。在小鼠MLL白血病移植瘤模型中,EPZ004777具有抗肿瘤和药效作用。

注意事项

请测试所有化合物在室内的溶解度,实际溶解度和理论值可能略有不同。这是由实验系统的误差引起的,属于正常现象。

References:

[1]. Yu W, Chory E J, Wernimont A K, et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors[J]. Nature communications, 2012, 3: 1288.

[2]. Daigle S R, Olhava E J, Therkelsen C A, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor[J]. Cancer cell, 2011, 20(1): 53-65.

质量控制

化学结构

EPZ004777